Fredun buys 26% of Goodman Vetcare, valuing pet-care chain at US$40.7M
What's the deal? Fredun PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has acquired a 26% stake in Goodman VetcareDealroom has a profile for this one. Try Dealroom →, valuing the pet-care retailer at roughly US$40.7M. The move pushes the drugmaker deeper into India's animal health and veterinary retail market.
Who's involved? Goodman Vetcare, founded in 1989, runs three stores in Mumbai and Navi Mumbai. Fredun makes antihypertensives, antidiabetics, ARVs, narcotics, and animal healthcare products, exporting mainly to Africa, Southeast Asia, CIS countries, and Latin America.
What's the endgame? The two plan to build an integrated pet-health platform, pairing Goodman's retail network with Fredun's manufacturing and technology. "The objective is to build a more integrated pet-health platform in India," said Fredun Medhora, managing director and chief financial officer of Fredun Pharmaceuticals.
By the numbers: Goodman grew revenue from US$1.91M in FY24 to US$3.2M in FY26 — a 30% annual rate — without institutional capital. It targets roughly US$5.43M by FY27, US$7.6M by FY28, and nearly US$13.6M by FY31.
The expansion: Goodman plans to open at least eight new stores across three cities, aiming for breakeven within three to four months per location. It intends to grow beyond Maharashtra by the end of 2027, backed by a new warehouse due in the first half of the year.
For Fredun, the deal is a small bet against a large base. It reported FY26 revenue of US$86.8M, EBITDA of US$12.9M, and profit after tax of US$4.51M.
What could go wrong? The revenue targets imply continued acceleration on a rising base, while multi-city expansion adds operational complexity. Goodman CEO Vipul Patil framed the partnership as backing "sustainable scaling rather than rapid overnight growth," crediting Fredun's pharmaceutical discipline in supply and quality management.
The signal: A generic drugmaker taking a minority stake in a niche pet-care chain reflects growing corporate interest in India's animal health market — and a bet that vertical integration between manufacturing and retail can outpace organic growth.
Image credit: www.ilmicrofono.it
